Last reviewed · How we verify

Oral Navelbine + Carboplatin — Competitive Intelligence Brief

Oral Navelbine + Carboplatin (Oral Navelbine + Carboplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy (vinca alkaloid + platinum agent). Area: Oncology.

phase 3 Combination chemotherapy (vinca alkaloid + platinum agent) Tubulin (vinorelbine); DNA (carboplatin) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Oral Navelbine + Carboplatin (Oral Navelbine + Carboplatin) — Sun Yat-sen University. Oral Navelbine (vinorelbine) inhibits microtubule assembly to arrest cancer cell division, while carboplatin causes DNA crosslinking and cell death, together providing synergistic cytotoxic activity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Oral Navelbine + Carboplatin TARGET Oral Navelbine + Carboplatin Sun Yat-sen University phase 3 Combination chemotherapy (vinca alkaloid + platinum agent) Tubulin (vinorelbine); DNA (carboplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy (vinca alkaloid + platinum agent) class)

  1. Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral Navelbine + Carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-navelbine-carboplatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: